Replies to post #140469 on Biotech Values

[DewDiligence]

Maybe [NVS] re-think the IDIX programs? Seems like they'd get a nuke + NS5 all under one-roof and put the past behind them.

For IDIX’s NS5A inhibitor, NVS doesn’t have to do any rethinking insofar as they have an exclusive option at the PoC stage (as they do with every new drug in IDIX’s pipeline).

For IDX184, on the other hand, NVS declined to exercise its option a few years ago, so NVS would indeed have to rethink its view of the drug’s prospects to become involved now. I don’t see such an action as likely, however; the case for NVS to license IDX184 is arguably weaker now than it was when NVS originally passed.